• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Basso Stephen was granted 1,353 shares and covered exercise/tax liability with 237 shares, increasing direct ownership by 5% to 23,518 units (SEC Form 4)

    5/22/25 4:15:16 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INVA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Basso Stephen

    (Last) (First) (Middle)
    1350 OLD BAYSHORE HIGHWAY, SUITE 400

    (Street)
    BURLINGAME CA 94010

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Innoviva, Inc. [ INVA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/15/2025 A 1,353(1) A $0 23,755 D
    Common Stock 05/20/2025 F 237(2) D $18.78 23,518 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Includes 1,353 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2025.
    2. The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
    /s/ Stephen Basso 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INVA

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    6/18/2024Overweight
    Cantor Fitzgerald
    7/20/2022$16.00Neutral
    Goldman
    2/23/2022$10.00 → $12.00Underweight
    Morgan Stanley
    2/11/2022$28.00Buy
    EF Hutton
    More analyst ratings

    $INVA
    SEC Filings

    See more
    • Innoviva Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Innoviva, Inc. (0001080014) (Filer)

      5/21/25 4:15:25 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Innoviva Inc.

      10-Q - Innoviva, Inc. (0001080014) (Filer)

      5/7/25 4:30:39 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Innoviva, Inc. (0001080014) (Filer)

      5/7/25 4:16:31 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Innoviva with a new price target

      Scotiabank initiated coverage of Innoviva with a rating of Sector Outperform and set a new price target of $55.00

      3/7/25 8:19:43 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Innoviva

      Cantor Fitzgerald initiated coverage of Innoviva with a rating of Overweight

      6/18/24 7:43:03 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Innoviva with a new price target

      Goldman initiated coverage of Innoviva with a rating of Neutral and set a new price target of $16.00

      7/20/22 7:30:02 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INVA
    Leadership Updates

    Live Leadership Updates

    See more

    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Innoviva Appoints Stephen Basso as Chief Financial Officer

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind

      8/25/23 4:52:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

      Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t

      7/11/23 8:00:00 AM ET
      $ARMP
      $INVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Innoviva Announces Retirement of Board Chairman

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v

      4/28/23 5:30:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

      FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adult

      6/12/25 7:00:00 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

      In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric pat

      6/10/25 6:00:00 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva to Participate in Upcoming Investor Conferences

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Format: Fireside chat Date: Monday, June 9, 2025 Time: 1:20 p.m. Eastern Time Scotiabank Third Annual Healthcare Canadian Investor Day Format: 1x1 meetings Date: Tuesday, June 17, 2025 A live webcast of the fireside chat from the Gold

      6/3/25 7:00:00 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 992 shares, decreasing direct ownership by 2% to 50,320 units (SEC Form 4)

      4 - Innoviva, Inc. (0001080014) (Issuer)

      5/22/25 4:15:51 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Basso Stephen was granted 1,353 shares and covered exercise/tax liability with 237 shares, increasing direct ownership by 5% to 23,518 units (SEC Form 4)

      4 - Innoviva, Inc. (0001080014) (Issuer)

      5/22/25 4:15:16 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Small Derek A was granted 12,077 shares, increasing direct ownership by 52% to 35,249 units (SEC Form 4)

      4 - Innoviva, Inc. (0001080014) (Issuer)

      5/21/25 9:36:44 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INVA
    Financials

    Live finance-specific insights

    See more
    • Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

      Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52% year-over-year growth Continued momentum across therapeutics platform with regulatory submissions for zoliflodacin and commercial launch of ZEVTERA® (ceftobiprole) progressing as planned Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today rep

      5/7/25 4:05:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

      Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year Innoviva Specialty Therapeutics achieved U.S. net product sales of $24.9 million for the fourth quarter and $80.9 million for the full year, reflecting 47% year-over-year growth Therapeutics platform strengthened with acquisition of exclusive U.S. commercialization and distribution rights to ZEVTERA® (ceftobiprole), launching mid-2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeuti

      2/26/25 4:04:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

      Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the

      11/6/24 4:05:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

      SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

      11/14/24 4:17:40 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Innoviva Inc.

      SC 13G - Innoviva, Inc. (0001080014) (Subject)

      5/13/24 1:58:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Innoviva Inc.

      SC 13D - Innoviva, Inc. (0001080014) (Subject)

      5/8/24 3:38:11 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care